Interactive modules by Olga Goodman, MD.Copyright protected · Read termsClose terms

All RheumaView™ interactive modules, quizzes and educational cases are original works developed by Olga Goodman, MD.

Without the author’s prior written permission, you may not copy or republish these modules or their components; extract, reuse or modify their original software code (“engines”); or use that code to build your own modules, quizzes or other products.

You may not claim these works as your own or remove or replace the author’s name or copyright notices. When quoting material, credit Olga Goodman, MD, identify the source and include a direct link to the original.

Free or public access is provided for learning and does not grant permission to copy, adapt or redistribute the materials. Unauthorized use of protected material may constitute copyright infringement. Exceptions and limitations provided by applicable law remain unaffected.

Sharing direct links to the modules is welcome.

© 2026 Olga Goodman, MD. All rights reserved.

Spondyloarthritis family · A closer look at PsA

PsA research directions: what is changing and what remains open

A dated reading selection on tissue biology, new treatment designs, molecular prediction and interception. Each entry separates the published evidence from the next question.

Olga Goodman, MD · Sources checked 27 September 2026

Chapter 21 of 21

The essentials

Promising science becomes useful through several steps: finding a signal, confirming it and showing that it improves decisions or outcomes. This selection is an evidence guide, not a treatment ranking or a complete list of trials.

Tissue biology: looking inside the enthesis

EBIO, published online in 2025, examined entheseal biopsies before and after IL-17A inhibition in 10 people. It offers a closer view of local biology. Its small cohort cannot establish a universal treatment-selection rule. 16

Why this matters: a blood sample may miss important activity in a particular tissue. The next question is whether a tissue signature can be reproduced and linked to a decision that benefits patients.

Treatment design: the ARGO phase 2 example

The 2025 ARGO publication reports a randomized trial of sonelokimab targeting IL-17A/F in 207 participants. The primary ACR50 comparison at week 12 favoured the induction regimens over placebo. The adalimumab reference arm was not powered to establish comparative superiority. 15

Why this matters: it tests a treatment design in patients, beyond a laboratory hypothesis. For practice, the relevant next evidence includes confirmatory trials, longer follow-up, safety and the applicable regulatory decision. This entry describes the cited publication, not a current prescribing authorization.

Molecular prediction: discovery versus a usable test

A 2026 secukinumab study analysed blood RNA in 13 treated patients and identified response-associated pathways and candidate markers. This is exploratory work requiring independent confirmation. 10

Integrate-PsA, published in 2026, sets out a prospective observational protocol to develop a treatment-response panel. A study plan does not yet supply a validated test. 11

Why this matters: a useful predictor could reduce time spent on ineffective treatment. To deliver that benefit, it must perform outside the development sample and improve decisions over clinical assessment alone.

Interception: acting before clinical arthritis

PAMPA tests a preventive treatment question; HPOS follows people with psoriasis to investigate risk. These designs have different purposes. Read their protocols and later reports separately. 5, 17

Why this matters: recognising risk could support earlier care. It does not automatically tell us who should receive preventive medication, for how long or with what balance of benefit and harm.

How to read the next update

This selection was reviewed on 27 September 2026. When a new report appears, compare it with the original protocol: same population, same endpoint, same assessment time? Look for the full report behind a conference abstract or press release.

Record what changed: a protocol became a results paper; a finding was independently reproduced; a longer follow-up clarified durability; or a regulator authorised a defined use. Each is a different kind of advance. A negative study can also improve care by closing an unhelpful path.

Go deeper

A compact evidence note you can reuse

Write six lines: study and date; people studied; design and comparator; main result with denominator and time; important uncertainty; implication for the question you actually have.

For participation in research, add the practical questions: visits, tests, randomisation, permitted background treatment, costs, travel and what happens if disease worsens. The consent discussion should explain how usual care continues and how withdrawal works. An invitation is not a promise of benefit.

Questions for your visit

  1. Is this a protocol, an exploratory result or a confirmatory trial?
  2. What would need to be shown before this changes my care?
  3. Where is the full report or registered study record?

When to seek urgent help

A painful red eye, light sensitivity or a sudden change in vision needs urgent assessment. A newly hot, swollen joint, especially with fever or feeling unwell, also needs prompt assessment.

Sources & evidence notes

Sources checked 27 September 2026

Dates identify the cited publications. Protocols, exploratory analyses and clinical results answer different questions. This is a selected reading route, not a complete evidence review.

  1. Haberman et al. PAMPA prevention trial protocol (2022; correction 2023).
  2. Abdul Jalil et al. Transcriptomic profiling of secukinumab-treated PsA (2026).
  3. Shekhar et al. Integrate-PsA: prospective observational study protocol (2026).
  4. McInnes et al. ARGO: sonelokimab phase 2 randomized trial (2025).
  5. EBIO. Entheseal tissue response to IL-17A inhibition; biopsy study (online 2025).
  6. Grohmann et al. HIPPOCRATES Prospective Observational Study protocol (2026).

Educational information for patients and caregivers. This personal publication is not the clinic portal and does not provide individual diagnosis or treatment. Discuss medication changes with your own care team.

© 2026 Olga Goodman, MD · A RheumaView publication. Copying without attribution prohibited.

Share this page

FacebookLinkedInXWhatsAppTelegram

Topics: Medical researchPsoriasisPsoriatic arthritisSpondyloarthritis